试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-09-24
Extension Study of Patidegib Topical Gel, 2% in Subjects With Gorlin Syndrome (Basal Cell Nevus Syndrome)
编号:NCT04308395登记状态:提前终止企业 / 申办者:Sol-Gel Technologies, Ltd.
药物 / 成分:Patidegib Topical Gel, 2%
登记的停止原因(原文):Study was terminated early due to low blinded event rate and this study termination is not related to safety of the drug Patidegib Topical Gel, 2%.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-09-24
A Study of Rilematovir (JNJ-53718678) in Adult Outpatients With Respiratory Syncytial Virus (RSV) Infection
编号:NCT04978337登记状态:提前终止企业 / 申办者:Janssen Research & Development, LLC
药物 / 成分:Rilematovir、Placebo
登记的停止原因(原文):Janssen made the strategic decision to discontinue the PRIMROSE study. This decision is not based on any safety concerns.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-09-24
An Open-Label Study of Trofinetide for the Treatment of Girls Two to Five Years of Age Who Have Rett Syndrome
编号:NCT04988867登记状态:提前终止企业 / 申办者:ACADIA Pharmaceuticals Inc.
药物 / 成分:Trofinetide
登记的停止原因(原文):As a result of marketing approval of trofinetide on 10 March 2023, the study was terminated by the Sponsor with the intent of switching patients to commercially available product.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-09-24
eXtended Antibiotic Prophylaxis for Intermediate- and High-risk Glands After Pancreatoduodenectomy to Reduce CR-POPF
编号:NCT05753735登记状态:提前终止企业 / 申办者:Case Comprehensive Cancer Center
药物 / 成分:Piperacillin/Tazobactam、Amoxicillin/ Clavulanic acid
登记的停止原因(原文):Principal investigator left the institution.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-09-24
A Phase 1b Study to Evaluate the Safety of XEN-101
编号:NCT06417697登记状态:提前终止企业 / 申办者:Xeno Biosciences
药物 / 成分:XEN-101、Placebo
登记的停止原因(原文):Study not stopped for safety reasons. Data were reviewed after the first 23 patients had completed scheduled dosing and there was no signal of efficacy for change in body weight. This clinical trial has been determined to be futile.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-09-23
A Study of CC-122 to Assess the Safety and Tolerability in Japanese Patients With Advanced Solid Tumors and Non-Hodgkin's Lymphoma (NHL)
编号:NCT02509039登记状态:提前终止企业 / 申办者:Celgene
药物 / 成分:CC-122
登记的停止原因(原文):Replaced it with another clinical trial.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-09-23
A Phase I Study of TQ-B3395 on Tolerance and Pharmacokinetics
编号:NCT02944864登记状态:提前终止企业 / 申办者:Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
药物 / 成分:TQ-B3395
登记的停止原因(原文):Per sponsor request.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-09-23
A Study of ABT-199 Plus Ibrutinib and Rituximab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
编号:NCT03136497登记状态:提前终止企业 / 申办者:Hackensack Meridian Health
药物 / 成分:400mg ABT-199、Ibrutinib、Rituximab、800mg ABT-199
登记的停止原因(原文):Lack of enrollment
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-09-23
A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe Kidney Disease
编号:NCT05487040登记状态:提前终止企业 / 申办者:Pfizer
药物 / 成分:PF-07321332 (nirmatrelvir)/ritonavir
登记的停止原因(原文):Decision to terminate study was due to slow enrolment and FDA input that available data may be enough for dosing recommendations for severe renal disease (subject to review by FDA).
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-09-20
A Phase Ib Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of Avelumab in Combination With M9241(NHS-IL12) (JAVELIN IL-12)
编号:NCT02994953登记状态:提前终止企业 / 申办者:EMD Serono Research & Development Institute, Inc.
药物 / 成分:Avelumab、M9241、Avelumab (Once weekly)、M9241 (MTD)
登记的停止原因(原文):The study was terminated due to pre-specified futility criteria met.
查看官方原始记录 ↗